Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $5.66M (cash outflow) rose 73.6% year over year, ahead of the +31.3% change in trailing-twelve-month net income. Sequentially, it fell 28.6% from the prior quarter. Over 3 fiscal years it compounded at +35.2% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$18.27M (-5.6%) for the fiscal year ending Dec 2026, a slowdown from the +22.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.66M-28.6% QoQ
- Last fiscal yearDec 2025
- -$19.36M+22.6% YoY
- LTMMar 2026
- -$21.76M+31.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +73.6% | +21.2% | -52.4 pp |
| 1 year | +22.6% | -5.6% | -28.2 pp |
| 3-year CAGR | +35.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (19.36M) USD
- Year-over-year change
- -22.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.36M) | -22.6% |
| FY2024 | 2024-12-31 | (15.79M) | -77.6% |
| FY2023 | 2023-12-31 | (8.89M) | -13.6% |
| FY2022 | 2022-12-31 | (7.83M) | -71.2% |
| FY2021 | 2021-12-31 | (4.57M) | — |
Net Income vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +31.3% is the 5th highest of 8, against a peer median of +67.3%.
- Over three fiscal years its annual growth of +35.2% compares with a peer median of +16.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $342.56M USD | +319.3% | +88.7% | 4571.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M USD | +82.4% | — | 892.4% |
| LTM Mar 2026 | $70.49M USD | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $62.51M USD | +132.2% | +0.2% | 50.5% | |
| LTM Mar 2026 | CA$35.52M CAD | +12.8% | +16.7% | — | |
| LTM Mar 2026 | $34.98M USD | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $30.92M USD | — | +47.5% | — | |
| LTM Mar 2026 | $21.76M USD | +31.3% | +35.2% | — | |
| LTM Mar 2026 | $19.58M USD | -41.2% | +3.2% | — | |
| Peer median (excluding GLSI) | — | +67.3% | +16.7% | 680.6% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.57M) | (7.83M) | (8.89M) | (15.79M) | (19.36M) |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Deferred Income Tax | (1.19M) | (1.75M) | 0 | 0 | 0 |
| Stock-Based Compensation | 660.58K | 1.74M | 2.38M | 7.25M | 6.8M |
| Change in Working Capital | (385.17K) | (122.27K) | 31.5K | 1.27M | 2.64M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (526.73K) | 0 | 35.47K | 921.22K | 2.07M |
| Other Working Capital | 141.57K | (122.27K) | (3.97K) | 344.11K | 568.12K |
| Other Non-Cash Items | 1.19M | 1.75M | 0 | 0 | 0 |
| Operating Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
| Capital Expenditures | 0 | (3) | 0 | 3 | 3 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 3.11M | 0 | 0 | 4.37M | 12M |
| Common Stock Repurchased | 0 | (7.54M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (275.15K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 2.84M | (7.54M) | 0 | 4.37M | 12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.46M) | (13.74M) | (6.48M) | (2.9M) | 2.09M |
| Free Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.